SP1 and cancer: Given that dysregulation of XPO1 directly contributes to tumor development, progression, and cancer drug resistance32–34, our findings implicate a regulatory mechanism underlying aberrant Wnt/β-catenin activation to promote PCa progression, hormone refractoriness, and DNPC development through enhancing SP1-regulated XPO1 activation.